Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report

BACKGROUND: Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma. CASE PRESENTATION: We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease (AERD), chronic rhinosinusitis, nas...

Descripción completa

Detalles Bibliográficos
Autores principales: Caruso, C., Colantuono, S., Pugliese, D., Di Mario, C., Tolusso, B., Gremese, E., Papparella, G., Castrì, F., Gasbarrini, A., Romano, A., Armuzzi, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178951/
https://www.ncbi.nlm.nih.gov/pubmed/32336975
http://dx.doi.org/10.1186/s13223-020-00423-3
_version_ 1783525570880995328
author Caruso, C.
Colantuono, S.
Pugliese, D.
Di Mario, C.
Tolusso, B.
Gremese, E.
Papparella, G.
Castrì, F.
Gasbarrini, A.
Romano, A.
Armuzzi, A.
author_facet Caruso, C.
Colantuono, S.
Pugliese, D.
Di Mario, C.
Tolusso, B.
Gremese, E.
Papparella, G.
Castrì, F.
Gasbarrini, A.
Romano, A.
Armuzzi, A.
author_sort Caruso, C.
collection PubMed
description BACKGROUND: Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma. CASE PRESENTATION: We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease (AERD), chronic rhinosinusitis, nasal polyposis and eosinophilic gastroenteritis successfully treated with MEP. Several laboratory and clinical items improved during therapy; moreover MEP showed to be useful as steroid sparing agent. CONCLUSIONS: This case supports that the use of mepolizumab can be effective also in other eosinophilic conditions different from asthma and this opens to new therapeutic perspectives.
format Online
Article
Text
id pubmed-7178951
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71789512020-04-26 Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report Caruso, C. Colantuono, S. Pugliese, D. Di Mario, C. Tolusso, B. Gremese, E. Papparella, G. Castrì, F. Gasbarrini, A. Romano, A. Armuzzi, A. Allergy Asthma Clin Immunol Case Report BACKGROUND: Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma. CASE PRESENTATION: We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease (AERD), chronic rhinosinusitis, nasal polyposis and eosinophilic gastroenteritis successfully treated with MEP. Several laboratory and clinical items improved during therapy; moreover MEP showed to be useful as steroid sparing agent. CONCLUSIONS: This case supports that the use of mepolizumab can be effective also in other eosinophilic conditions different from asthma and this opens to new therapeutic perspectives. BioMed Central 2020-04-22 /pmc/articles/PMC7178951/ /pubmed/32336975 http://dx.doi.org/10.1186/s13223-020-00423-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Caruso, C.
Colantuono, S.
Pugliese, D.
Di Mario, C.
Tolusso, B.
Gremese, E.
Papparella, G.
Castrì, F.
Gasbarrini, A.
Romano, A.
Armuzzi, A.
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
title Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
title_full Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
title_fullStr Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
title_full_unstemmed Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
title_short Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
title_sort severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178951/
https://www.ncbi.nlm.nih.gov/pubmed/32336975
http://dx.doi.org/10.1186/s13223-020-00423-3
work_keys_str_mv AT carusoc severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT colantuonos severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT pugliesed severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT dimarioc severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT tolussob severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT gremesee severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT papparellag severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT castrif severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT gasbarrinia severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT romanoa severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport
AT armuzzia severeeosinophilicasthmaandaspirinexacerbatedrespiratorydiseaseassociatedtoeosinophilicgastroenteritistreatedwithmepolizumabacasereport

Ejemplares similares